

Contents

Cancer Research

November 15, 2010 • Volume 70 • Number 22

BREAKING ADVANCES

- 8971 | **Highlights from Recent Cancer Literature**

REVIEWS

- 8973 | **Breast Cancer Stem Cells: Something Out of Notching?**
Hannah Harrison, Gillian Farnie, Keith R. Brennan, and Robert B. Clarke
- 8977 | **Turning on a Fuel Switch of Cancer: hnRNP Proteins Regulate Alternative Splicing of Pyruvate Kinase mRNA**
Mo Chen, Jian Zhang, and James L. Manley

PRIORITY REPORTS

- 8981 | **Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1**
Meghan J. Seltzer, Bryson D. Bennett, Avadhut D. Joshi, Ping Gao, Ajit G. Thomas, Dana V. Ferraris, Takashi Tsukamoto, Camilo J. Rojas, Barbara S. Slusher, Joshua D. Rabinowitz, Chi V. Dang, and Gregory J. Riggins
- Précis: IDH1 mutations create a higher dependence of glioma cells on α -ketoglutarate, relative to normal cells, that could be therapeutically exploited by targeting glutamine metabolism.*

- 8988 | **Heat Shock Protein 60 Regulation of the Mitochondrial Permeability Transition Pore in Tumor Cells**
Jagadish C. Ghosh, Markus D. Siegelin, Takehiko Dohi, and Dario C. Altieri
- Précis: Findings implicate a chaperone network in controlling mitochondrial permeability transition and apoptosis in cancer cells.*

CLINICAL STUDIES

- 8994 | **The Ability of Biomarkers to Predict Systemic Progression in Men with High-Risk Prostate Cancer Treated Surgically Is Dependent on ERG Status**
R. Jeffrey Karnes, John C. Cheville, Cristiane M. Ida, Thomas J. Sebo, Asha A. Nair, Hui Tang, Jan-Marie Munz, Farhad Kosari, and George Vassmatzis

Précis: The study presents TOP2A as a superior prognostic marker for prostate cancer and shows that its predictive ability is dependent on cancer subtype.

- 9003 | **Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis**
Victoria A. Brown, Ketan R. Patel, Maria Viskaduraki, James A. Crowell, Marjorie Perloff, Tristan D. Booth, Grygoriy Vasilinin, Ananda Sen, Anna Maria Schinas, Gianfranca Piccirilli, Karen Brown, William P. Steward, Andreas J. Gescher, and Dean E. Brenner

Précis: This study defines suitable doses, accompanying blood levels, and potential efficacy biomarkers which might help to optimize future cancer chemoprevention intervention studies of the red wine constituent resveratrol.

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

Yangbing Zhao¹, Edmund Moon², Carmine Carpenito¹, Chrystal M. Paulos¹, Xiaojun Liu¹, Andrea L. Brennan¹, Anne Chew¹, Richard G. Carroll¹, John Scholler¹, Bruce L. Levine¹, Steven M. Albelda², and Carl H. June¹

Abstract

Redirecting T lymphocyte antigen specificity by gene transfer can provide large numbers of tumor-reactive T lymphocytes for adoptive immunotherapy. However, safety concerns associated with viral vector production have limited clinical application of T cells expressing chimeric antigen receptors (CAR). T lymphocytes can be gene modified by RNA electroporation without integration-associated safety concerns. To establish a safe platform for adoptive immunotherapy, we first optimized the vector backbone for RNA *in vitro* transcription to achieve high-level transgene expression. CAR expression and function of RNA-electroporated T cells could be detected up to a week after electroporation. Multiple injections of RNA CAR-electroporated T cells mediated regression of large vascularized flank mesothelioma tumors in NOD/scid/ $\gamma c(-/-)$ mice. Dramatic tumor reduction also occurred when the preexisting intraperitoneal human-derived tumors, which had been growing *in vivo* for >50 days, were treated by multiple injections of autologous human T cells electroporated with anti-mesothelin CAR mRNA. This is the first report using matched patient tumor and lymphocytes showing that autologous T cells from cancer patients can be engineered to provide an effective therapy for a disseminated tumor in a robust preclinical model. Multiple injections of RNA-engineered T cells are a novel approach for adoptive cell transfer, providing flexible platform for the treatment of cancer that may complement the use of retroviral and lentiviral engineered T cells. This approach may increase the therapeutic index of T cells engineered to express powerful activation domains without the associated safety concerns of integrating viral vectors. *Cancer Res*; 70(22); 9053–61. ©2010 AACR.

Introduction

Adoptive transfer of CTLs has shown great promise in both viral infections and cancers. After many years of disappointing results with chimeric antigen receptor (CAR) T-cell therapy, improved culture systems and cell engineering technologies are leading to CAR T cells with more potent anti-tumor effects (1). Results from recent clinical trials indicate improved clinical results with CARs introduced with retroviral vectors (2, 3). Perhaps not surprisingly, these CAR T cells

also exhibit enhanced toxicity (4, 5). Recent editorials have discussed the need for safer CARs (6, 7).

The receptor transfer strategies described above used retroviral vector transduction that results in stable genomic integration of the transgene. This allows for constitutive expression of the transgenic receptors. However, the integration of the provirus into the genome bears the risk of insertional mutagenesis and, at least theoretically, malignant transformation of the transduced cells. In addition, stable expression of the transgene may be a disadvantage when unintended cross-reactivity of the transgenic immunoreceptor results in severe adverse effects as reported recently (5, 8).

Here, we report that by combining a robust T-cell culture system (9) with the optimized mRNA CAR electroporation protocol described herein, we have developed a platform that has the potential to increase the therapeutic window with CARs that contain increasingly potent signaling domains. Using good manufacturing practice (GMP)-grade RNA encoding a CAR against mesothelin, a glycosylphosphatidylinositol-linked molecule that is overexpressed on ovarian and pancreatic cancer and mesothelioma (10), we show robust antitumor effects in preclinical models. Most notably, significantly prolonged survival and reduced tumor burden was observed in treated mice compared with

Authors' Affiliations: ¹Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine and ²Thoracic Oncology Research Laboratory and Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Y. Zhao and E. Moon contributed equally to this work.

Corresponding Authors: Carl H. June or Yangbing Zhao, University of Pennsylvania, 551 BRB 2/3, 421 Curie Boulevard, Philadelphia, PA 19104-6160. Phone: 215-746-5133; Fax: 610-646-8455; E-mail: cjune@exchange.upenn.edu or yangbing@exchange.upenn.edu.

doi: 10.1158/0008-5472.CAN-10-2880

©2010 American Association for Cancer Research.

control groups, even when using autologous T cells from a patient with advanced metastatic cancer. Electroporation of T cells with optimized RNA CARs provides a novel and cost-efficient platform for the treatment of cancer without the associated safety concerns of integrating gene vectors.

Materials and Methods

Construction of *in vitro* transcription mRNA vectors for CARs

Mesothelin (ss1) and CD19-specific CARs (11, 12) were optimized as described in detail in Supplementary Materials and Methods.

RNA *in vitro* transcription

Three RNA *in vitro* transcription (IVT) systems were used to optimize RNA expression in T cells as described in detail in Supplementary Materials and Methods.

T-cell culture

Anonymous healthy donors donated lymphocytes at the University of Pennsylvania Apheresis Unit after informed consent under an Institutional Review Board-approved protocol, and T cells were purified by elutriation. In some experiments, we used cryopreserved T cells and tumor cells from the same patient. "Patient 108" had malignant mesothelioma. As part of an earlier clinical trial, this patient underwent leukapheresis and had tumor cells generated from his malignant pleural effusion. T cells were activated by addition of CD3/CD28 beads (Invitrogen) and a single cycle of stimulation as described (9). For the experiment shown in Fig. 5, patient 108 T cells were stimulated with irradiated antigen-presenting cells expressing 4-1BBL and loaded with anti-CD3 monoclonal antibody (mAb) OKT3 and CD28 mAb 9.3 as described (13). T cells were maintained at a density of 0.8×10^6 to 1×10^6 cells/mL in RPMI 1640 with 10% FCS and 1% penicillin-streptomycin (R10) after bead stimulation.

RNA electroporation of T cells

Activated T cells were electroporated on day 10 of culture as described in Supplementary Materials and Methods.

Flow CTL

A slightly modified version of a flow cytometry cytotoxicity assay was used (14).

Mouse xenograft studies

Studies were performed as previously described with certain modifications (15, 16) as described in Supplementary Materials and Methods.

Statistical considerations

Analysis was performed with STATA version 10 (Stata-Corp) or Prism 4 (GraphPad Software). *In vitro* data represent means of duplicates, and comparisons of means were made via Mann-Whitney test. For comparison among multiple groups, Kruskal-Wallis analysis was performed with Dunn

multiple comparison tests to compare individual groups. Survival curves were compared using the log-rank test with a Bonferroni correction for comparing multiple curves.

Results

Electroporation of RNA CARs mediates variable expression in stimulated T cells

We have previously reported that anti-mesothelin ss1 scFv CARs with combinations of CD3 ζ , CD28, and 4-1BB activation domains are highly and stably expressed in T cells when introduced using lentiviral vector technology (11). Human T cells were activated for 10 days as previously described (9), and as the cells returned to a near resting state, they were electroporated with RNA encoding the ss1 scFv with the previously described combinations of signaling moieties. We found that the level of transgene expression was not uniform (Supplementary Fig. S1), as T cells electroporated with CAR bearing CD3 ζ alone (ss1-z) showed the highest transgene expression, followed by nearly equivalent levels of ss1-28z (CD28 + CD3 ζ) and ss1-bbz (4-1BB + CD3 ζ) expression. Because "second-generation" CARs containing costimulation domains seem superior in several preclinical and early-stage clinical trials when expressed with viral vector systems (11, 12, 17, 18), we decided not to optimize expression of the "first-generation" ss1-z CAR. Rather, the second-generation ss1-bbz and CD19-bbz CARs were chosen for further optimization using RNA electroporation because they are being tested in a clinical trial using lentiviral vector technology (Clinicaltrials.gov NCT00891215).

Optimization of RNA constructs improves transgene expression in stimulated T cells

Structural modification of noncoding regions by incorporation of two repeats of 3' untranslated regions (UTR) from β -globulin and longer poly(A) sequences has been shown to enhance RNA stability, translational efficiency, and the function of RNA-transfected dendritic cells (19). However, these strategies have not been systematically evaluated in RNA-electroporated T cells. To test if this approach applies to human T lymphocytes, we modified our IVT vector (pGEM-ss1bbz.64A) by adding 5'UTR (SP163) or 3'UTR [two repeats of 3'UTR derived from human β -globulin (2bgUTR) or a prolonged poly(A) (150A) sequence as shown in Fig. 1A]. The SP163 translational enhancer is derived from the 5'UTR of the vascular endothelial growth factor gene and is reported to increase expression levels 2- to 5-fold compared with promoter alone (20). RNA made from these constructs was electroporated into stimulated T cells. As shown in Fig. 1B, compared with our basic IVT construct containing a 64-poly(A) tract, addition of 3'UTR from β -globulin (2bgUTR) and longer poly(A) (150A) tailing enhanced the transgene expression, especially when combined (2bgUTR.150A). In contrast, incorporation of the SP163 sequence at the 5' end of ss1-bbz repressed transgene expression, which might be due to reduced capping efficiency when the SP163 sequence was added.




Figure 1. Optimization of mRNA by modification of the UTRs confers high-level expression of CARs in electroporated T cells. A, a schematic representation of ss1-bbz construct with different modifications of 5'UTR or 3'UTR. pGEM-based IVT vector containing ss1-bbz (pGEM-ss1bbz.64A) was modified as described in Materials and Methods to add a 3'UTR (2bgUTR.64A), a 5'UTR (SP163.64A), a longer poly(A) tail (150A), or both 3'UTR and longer poly(A) (2bgUTR.150A). B, RNA made from the modified constructs was electroporated into T cells and the transgene expression was followed by flow cytometry. Left, histograms of the transgene expression at day 1 after electroporation; right, mean fluorescence intensity (MFI) of the CAR for 4 d after electroporation. Experiments are representative of at least two independent experiments.

Optimization of the 5' cap structure enhances the expression and function of CARs in electroporated T cells

The 5' cap located at the end of mRNA molecule consists of a guanine nucleotide connected to the mRNA via a 5' to 5' triphosphate linkage. Several cap structures have been described, including caps 0 and 1 (21). Several methods have been used to incorporate the 5' cap structure onto the transgene and poly(A) tail construct. Commercially available systems incorporate cap 0 or 1 using cotranscriptional or enzymatic approaches to produce capped mRNA. This process is important to optimize to enhance translational efficiency and because of the considerable expense of the various capping systems (see Supplementary Materials and Methods). RNA made using the different capping systems was electroporated into stimulated T cells, and the transgene expression was monitored by flow cytometry (Fig. 2A and B). The results showed that the transgene expression of T cells electroporated with RNA capped by anti-reverse cap analogue (ARCA) was 3-fold higher than regular cap (RC) analogue capped RNA at 4 hours. The transgene persistence of ARCA capped RNA was also improved, as at day 5 after electroporation >50% of the T cells still expressed the CAR as shown in Fig. 2B.

We next compared enzymatic addition of caps 0 and 1 to nonenzymatic addition of the ARCA. The potential advantage of using the capping enzyme (CE) system is that this approach includes CE and mScript 2'-O-methyltransferase that work together to produce the cap1 structure, which is very similar to ARCA and provides superior translation efficiency in many *in vivo* systems. To evaluate the efficiency of cap 0 or 1 RNA encoding ss1-bbz, human T cells were electroporated with RNA made by ARCA, CE, cap1 CEs, or CEs plus additional poly(A). As shown in Fig. 2C, the CAR expression using cap1 RNA electroporation was equivalent to ARCA IVT mRNA. The transgene expression was further enhanced by incorporation of the longer poly(A) tail, consistent with the results in Fig. 1.

One potential functional advantage of optimized IVT RNA is that CAR expression could be sustained, as translation of additional CAR could lead to more persistent expression and overcome downregulation induced by target recognition or homeostatic expansion. Activated T cells were electroporated with various RNA preparations encoding ss1-bbz, and then cocultured with K562-meso or control K562-CD19 target cells for 2 days (Supplementary Fig. S2). T cells electroporated with ARCA and CE1 or CE1+A capped ss1-bbz RNA could still maintain their transgene expression

after being stimulated with the K562-meso cell line compared with the same T cells cocultured with control target cells. In contrast, T cells electroporated with ss1-bbz RNA capped by the RC analogue did not have detectable CAR on the surface after cocultured with antigen-bearing target.

Based on the above results and other data (data not shown), we concluded that RNA capped with ARCA or with cap1 and a long poly(A) tail is the best RNA production system among the RNAs tested. For large-scale GMP production of IVT RNA, when the production cost is also considered, cap1 is preferred.

In vitro function of optimized IVT RNA CARs

RNAs prepared from both plasmids bearing parental or internal ORF-free CAR sequences were electroporated into T cells, and it was found that the transgene expression from the RNAs with internal ORF-free electroporated T cells was equivalent to the T cells electroporated with RNAs with parental sequences (Supplementary Fig. S3) at 20 hours after electroporation. However, substantial prolongation of CAR expression was observed in activated T cells electroporated with clinical-grade RNA generated from internal ORF-free pD-A.ss1.OF or pD-A.19.OF RNAs using the CE system that incorporated both cap1 and prolonged poly(A) into the IVT RNAs (Fig. 3). Transgene expression of the optimized IVT RNA could be detected as long as 7 days after RNA electroporation for both meso and CD19 RNA CARs as shown in Fig. 3C.

Previous studies have shown that 4-1BB is upregulated on CD8⁺ T cells after T-cell receptor stimulation (22). We incubated bulk T cells electroporated with ss1-bbz or CD19-bbz RNA with target cells expressing either mesothelin or CD19, and found robust upregulation of 4-1BB, particularly on CD8⁺ T cells, which was target specific (Fig. 3A). The T cells expressing

RNA CARs also secreted substantial amounts of interleukin-2 (IL-2) and translocated CD107a on target-specific recognition (Fig. 3B and D). Finally, in a flow-based lytic assay, we found that both CD19 (19.OF) and ss1 (ss1.OF) CAR RNA-electroporated T cells could specifically lyse target cells efficiently (Supplementary Fig. S4).

RNA-electroporated T cells mediate regression of human disseminated mesothelioma xenografts

A pilot experiment was first conducted to evaluate the therapeutic potential of T cells expressing optimized RNA CARs in mice bearing large pre-established tumors. Mesothelin-positive tumors were established in NSG mice as previously reported (11). Sixty-six days after tumor inoculation, 10×10^6 to 15×10^6 ss1-bbz RNA CAR-electroporated T cells from a healthy donor were injected intratumorally, twice weekly for 2 weeks. The biweekly administration schedule was based on the *in vitro* expression data shown in Fig. 3. As seen in Fig. 4A, the tumors regressed in the mice treated with ss1 RNA-electroporated T cells, whereas progressive tumor growth was observed in the control group of mice. At the time the mice were sacrificed on day 98, tumor size was substantially smaller in all of the mice treated with electroporated T cells than that of the mice treated with saline (Supplementary Fig. S5). These results indicate therapeutic potential of multiple injections of RNA CAR T cells; however, they are not as potent in the same tumor model using lentiviral transduced T cells, where two intratumoral injections of T cells were able to cure most mice (11).

We developed the M108-Luc model to test if RNA CAR-electroporated T cells are capable of treating mice bearing large disseminated tumors. M108 parental cells were stably transduced with firefly luciferase to allow for bioluminescence imaging (BLI), and in preliminary experiments, we




Figure 2. Optimization of RNA capping enhances and sustains CAR expression on electroporated T cells. A, T cells were electroporated with IVT RNA capped by the indicated capping method, including using RC analogue, ARCA, or CE at a fixed RNA dose of 2.5 $\mu\text{g}/100 \mu\text{L}$ T cells. Transgene expression was monitored by measuring MFI using flow cytometry at the indicated times after electroporation (EP). B, T cells from the above experiment were monitored by flow cytometry to determine the fraction of cells expressing the transgene. C, T cells electroporated with IVT RNA encoding ss1-bbz capped by different capping methods, including ARCA, CE, CE with addition poly(A) (CE+A), CE system-generated cap1 RNA (CE1), or CE system-generated cap1 RNA plus enzymatic poly(A) (CE1+A) at an RNA dose of 10 $\mu\text{g}/100 \mu\text{L}$ T cells. Transgene expression was monitored by flow cytometry (MFI) for 3 d after electroporation. Experiments are representative of two independent experiments.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.